CRF Health’s TrialMax Touch® Selected for Pediatric Rare Disease Phase II Study


Applied Clinical Trials

CRF Health has been selected by a specialty pharmaceutical company for its latest pediatric rare disease Phase II study. CRF Health's TrialMax Touch® handheld device alone with other solutions will be utilized to collect quality of life readings and alleviate the burden of data entry for caregivers. 

Read the full release here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.